Background: Restenosis after carotid endarterectomy (CEA) is associated with an increased risk of stroke, and the management of critical or symptomatic restenotic lesions poses a treatment challenge. The superiority of CEA vs carotid angioplasty and stenting (CAS) for restenosis remains debatable because existing studies are few and limited by small sample size or the inability to align interventions with ipsilateral events beyond the periprocedural period. We performed a population-based evaluation of CEA vs CAS in a large contemporary cohort of patients with carotid artery restenosis.
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1 Reports of restenosis from observational studies range from 6% to 22%, with the variation largely due to differences in the definition of restenosis and duration of follow-up. [2] [3] [4] Restenosis after CEA is associated with an increase in the risk of stroke, as revealed by the results from CREST. 1 That landmark clinical trial found a fourfold increase in stroke risk for patients with restenosis compared with patients without restenosis. 1 Prior surgery imposes anatomic high-risk conditions for redo CEA, and carotid angioplasty and stenting (CAS) has been popularized as a viable alternative to surgery in high-risk patients. However, objective comparisons of CEA vs CAS in a large and recent cohort of patients with prior CEA are lacking. Previous studies on the subject have been limited to institutional series and regional registries. [5] [6] [7] [8] [9] [10] [11] Notable, these studies were based on relatively small numbers of patients, thus limiting the power to detect differences between CEA and CAS. For these reasons, the superiority of surgery vs endovascular treatment in these patients remains the subject of significant debate. Factors such as female gender, diabetes mellitus, hyperlipidemia, and active smoking have been shown to influence the incidence of restenosis after CEA. 1 However, little is known of the effect these factors have on outcomes after treatment for carotid restenosis. Advances in the techniques for carotid revascularization and improved medical therapy warrant a contemporary evaluation of the treatment options for carotid restenosis. CEA and CAS are known to be performed more frequently in asymptomatic patients, hence the need to evaluate treatment durability and identify targets for minimizing adverse outcomes. The objective of this study was to evaluate real-world outcomes after CEA vs CAS in a large contemporary population-based cohort of patients with prior ipsilateral CEA and also to identify risk factors for adverse outcomes.
METHODS
We performed a retrospective analysis of all patients in the Vascular Quality Initiative (VQI) who underwent CEA or CAS between January 1, 2003, and April 30, 2015, after a prior ipsilateral CEA. The VQI is a prospectively maintained database approved by the Society for Vascular Surgery. It contains patient and procedure-specific data from multiple sites across all regions of the United States and incorporates data on mortality from the Social Security Death Index. At the end of the study period, there were >370 hospitals and 2800 participating physicians in the VQI. Details of the data collection and validation process have been published previously. 12 The current study was approved by the VQI Research Advisory Committee, and the Johns Hopkins Institutional Review Board waived the need for individual patient consent under the provisions for deidentified human subject and quality improvement research. Patients who underwent CEA or CAS after ipsilateral CEA were identified directly from variables recorded in the VQI database. The relevant patient and procedurerelated data assessed are listed in Tables I and II . Symptomatic status was defined as the occurrence of ipsilateral stroke, transient ischemic attack, or amaurosis fugax before treatment. The interval between symptom and treatment was also examined. Postoperative outcomes (30 days) were ipsilateral stroke, myocardial infarction (MI), death, and the composites of stroke/death and stroke/death/MI. Outcomes at 1 year were stroke, death, and stroke/death. Stroke was defined as the occurrence of minor or major, ocular or cortical stroke after surgery or intervention. MI was a clinical or electrocardiogram-confirmed diagnosis or an elevation in troponins. Complications examined were cranial nerve injury, wound infection, access site complications, including hematoma or arterial occlusion, and procedurally related arrhythmia.
Statistical methods. Descriptive analyses of the study groups were performed using c 2 and Student t-tests as appropriate. Univariable and multivariable logistic regression analyses were used to evaluate 30-day postoperative outcomes and identify their predictors. Kaplan-Meier (KM) estimates were computed, and related curves were constructed to compare the survival function between the treatment groups. The log-rank and Wilcoxon tests were applied to test the equality of survival functions.
Univariable and multivariable Cox regression methods were used to analyze the 1-year outcomes and identify their predictors. Variables included in the multivariate model were based on the univariable analysis, prior literature, guidance of likelihood ratio tests, and Akaike information indices, with a goal to achieve model parsimony.
Clinically relevant variables and others known to influence outcomes after carotid revascularization were forced into the models obtained from a stepwise selection process. After examining real-world outcomes from the complete case analyses, we used 1:1 propensity score-matched analyses to simulate an evaluation of similar groups of CEA and CAS patients. The treatment groups were matched on age, gender, race, symptomatic status, hypertension, diabetes, coronary artery disease, congestive heart failure, chronic obstructive pulmonary disease, American Society of Anesthesiologists (ASA) Physical Status Classification, degree of ipsilateral stenosis, contralateral occlusion, and smoking status. We performed sensitivity analyses comparing characteristics and outcomes of patients with complete follow-up data at 30 days, 6 months, and 1 year to assess for selection bias resulting from loss to follow-up. Analyses were performed using Stata 14.1 statistical software (StataCorp LP, College Station, Tex). Statistical significance was accepted at P < .05.
RESULTS
Patient characteristics. Between January 1, 2003, and April 30, 2015, 2863 carotid interventions were performed in patients with a prior ipsilateral CEA. Of these, 1047 (37%) were redo CEA and 1816 (63%) were CAS. The CEA and CAS cohorts were similar in age (mean: both 70 years; P ¼ .15), female gender (CEA: 42.3%, CAS: 45.4%; P ¼ .11), and Caucasian race (CEA: 95.3%, CAS: 95.1%; P ¼ .44; Table I ). Comparing CEA vs CAS, the prevalence of diabetes mellitus (35% vs 36%; P ¼ .55), hypertension (91% vs 93%; P ¼ .043), coronary artery disease (32% vs 34%; P ¼ .40), and symptomatic status (32% vs 34%; P ¼ .26) was similar between the groups. Active smoking was slightly more prevalent in the CEA cohort (37% vs 30%; P < .001).
Overall, 53% of CEA and 49% of CAS patients had a follow-up duration >30 days (P ¼ .02), 48% of CEA and 44% of CAS patients had a follow-up duration >6 months (P ¼ .034), and 35% of CEA and 32% of CAS patients had follow-up data at 1 year (P ¼ .072). The mean follow-up duration for patients with follow-up >30 days was 371 days (standard deviation, 160; median, 380; interquartile range, 294-439 days) days for CEA and 365 days (standard deviation, 163; median, 374; interquartile range, 291-433 days) for CAS (P ¼ .54). The characteristics of redo CEA vs CAS patients with complete follow-up data at 30 days, 6 months, and 1 year were similar (Table II) . The sensitivity analyses showed no significant difference in results obtained from the subcohorts of patients with complete follow-up at 6 months and 1 year compared with the overall cohort. The results from the complete case analyses follow.
Thirty-day postoperative outcomes. Overall, 45 (1.6%) patients sustained an ipsilateral stroke #30 days of the procedure. Of these, 20 (2.0%) occurred after CEA and 25 (1.4%) after CAS (P ¼ .27). When stratified by preoperative symptoms, 30-day postoperative stroke rate comparing CEA vs CAS was 2.2% vs 1.3% (P ¼ .098) for asymptomatic patients and 1.2% vs 1.6% (P ¼ .60) for symptomatic patients (Table III) . Mortality at 30 days was significantly higher after CEA than after CAS (1.3% vs 0.6%, P ¼ .043). However, MI (1.4% vs 1.1%; P ¼ .44) and the composite of stroke/death (2.7% vs 1.9%; P ¼ .16) and stroke/death/MI (3.8% vs 2.8%; P ¼ .12) rates were similar between the treatment groups (Table III) .
Cranial nerve injury and wound infection occurred in 4.1% and 0.4% of the redo CEA cases, respectively. Technical failure and access site complications occurred in 0.6% and 5.3% of the CAS cases, respectively. The incidence of procedure-related arrhythmias was 1.7% for CEA and 1.5% for CAS (P ¼ .64).
The multivariable logistic regression analyses showed that there was no significant difference in the odds of perioperative stroke after CEA compared with CAS (odds ratio One-year outcomes. Overall, 57 (2%) ipsilateral stroke events occurred during the study period: 21 (2%) after CEA and 36 (2%) after CAS (P ¼ .969). The absolute ipsilateral stroke rate was 2% (CEA: 2.4%; CAS: 1.8%; P ¼ .341) for asymptomatic patients and 2% (CEA: 1.2%; CAS: 2.5%; P ¼ .194) for symptomatic patients. Stroke estimates at 1 year obtained from the KM analyses were 3.3% (95% CI, 2.2-5.1) for CEA vs 3.6% (95% CI, 2.5-5.0) after CAS (P ¼ .78 by log-rank). By symptomatic strata, 1-year stroke estimates from KM for CEA vs CAS were 4.1% (95% CI, 2.5-6.5) vs 3.3% (95% CI, 2.1-5.1) for asymptomatic patients (P ¼ .44 by logrank; Fig 1) and 1.9% (95% CI, 0.7-5.0) vs 4.3% (95% CI, 2.4-7.4) for symptomatic patients (P ¼ .11 by log-rank; Fig 2) . The multivariable Cox regression analyses showed that there was no significant difference in freedom from stroke for CEA compared with CAS (adjusted hazard ratio [aHR], 0.98; 95% CI, 0.47-2.09; P ¼ .97) adjusting for age, gender, race, symptoms, degree of stenosis, diabetes, hypertension, and smoking (Table V) . Freedom from stroke was also similar for symptomatic patients compared with asymptomatic patients (aHR, 1.34; 95% CI, 0.72-2.5; P ¼ .36).
Absolute all-cause mortality was 6.5% (CEA: 8.2%, CAS: 5.6%; P ¼ .006) over the entire study period. The KM estimates of mortality at 1 year were 6% (95% CI, 4.4-8.0) after CEA vs 5.4% (95% CI, 4.2-6.9) after CAS (P ¼ .69 by log-rank; Fig 3) . By symptomatic strata, 1-year KM mortality estimates for asymptomatic patients were 5.2% (95% CI, 3.6-7.7) for CEA vs 5.1% (3.7-7.0) for CAS (P ¼ .88 by logrank) and for symptomatic patients were 7.5% (95% CI, 4.7-11.8) for CEA vs 6.1% (3.9-9.3) for CAS (P ¼ .73 by logrank). The multivariable Cox regression analyses showed higher mortality associated with CEA than with CAS (aHR, 2.17; 95% CI, 1.03-4.58; P ¼ .042). Survival was similar between symptomatic and asymptomatic patients (aHR, 0.94; 95% CI, 0.61-1.45; P ¼ .78).
The absolute stroke/death rate over the study period was 8.4% (CEA: 9.9%, CAS: 7.5%; P ¼ .029). There was no difference in this composite outcome in the adjusted analyses (aHR, 1.42; 95% CI, 0.77-2.62; P ¼ .262) for CEA vs CAS. The predictors of stroke/death after CEA were older age (aHR, 1.08; 95% CI, 1.05-1.12; P < .001), active smoking (aHR, 1.94; 95% CI, 1.06-3.52; P ¼ .03), congestive heart failure (aHR, 2.46; 95% CI, 1.28-4.76; P ¼ .01), and ASA class IV (aHR, 2.10; 95% CI, 1.18-3.72; P ¼ .011) compared with patients in ASA class III (Table VI) . The predictors of stroke/death after redo CAS were older age (aHR, 1.05; 95% CI, 1.02-1.07; P < .001), chronic obstructive pulmonary disease (aHR, 1.66; 95% CI, 1.07-2.57; P ¼ .02), and ASA class IV (aHR, 2.86; 95% CI, 1.76-4.65; P < .001) compared with patients in ASA class III (Table VII) treatment of carotid restenosis in patients with a prior ipsilateral CEA. To our knowledge, this is the largest population-based study to date on the subject and the first to reveal higher mortality after redo CEA than after CAS in these patients. The higher mortality associated with CEA was evident in the 30-day postoperative period and extended up to 1 year, despite adjustment for patients' characteristics. Previous studies contained many fewer patients and reported no difference in mortality between CEA and CAS. [5] [6] [7] [8] [9] [10] [11] A meta-analysis of existing studies by Fokkema et al 13 evaluated 479 redo CEA and 653 CAS cases performed after prior ipsilateral CEA. That study revealed 30-day postoperative mortality of 0.6% after CEA and 0.6% after CAS in contrast to our report of 1.3% for CEA vs 0.6% for CAS. Notably, the largest contributing study to that meta-analysis contained only 212 CEA and 220 CAS patients. 8 Although we are unable to ascertain the cause of death in these patients, the more prevalent use of general anesthesia during CEA likely contributes to the higher mortality. In the combined analyses of CEA and CAS cohorts, general anesthesia was associated with a fivefold increase (aOR, 4.68; 95% CI, 1.30-16.87, P ¼ .004) in 30-day postoperative mortality, and 96% of CEA vs 13% of CAS procedures were performed under general anesthesia. General anesthesia was identified as a predictor of adverse outcomes in CREST, 14 and a recent systematic review showed mortality after CEA was 1.5% after general anesthesia vs 0.9% after locoregional anesthesia, although the trend did not reach statistical significance. 15 This negative effect of general anesthesia raises the potential benefit for redo CEA performed under regional anesthesia. However, the technical difficulty associated with dissecting through distorted anatomic planes during redo CEA undermines the benefit of this alternative. When compared with outcomes from the CREST trial, which enrolled patients with de novo carotid lesions, and those in the Stenting with Angioplasty and Protection in Patients at High Risk for Endarterectomy (SAP-PHIRE) trial, which enrolled high-risk patients, 30-day postoperative mortality after redo CEA in the current study (1.3%) was higher than the report of 0.3% from the CREST trial 16, 17 but lower than the 2.5% reported from the SAPPHIRE trial. 5, 18 However, our report of 0.6% mortality after CAS in patients with prior CEA was similar to the 0.7% reported from CREST and 0.6% reported from SAPPHIRE. 18 The mortality results from the current study fall well within the acceptable range as stipulated by the Society for Vascular Surgery and others. 19 This suggests that CEA and CAS after prior ipsilateral CEA are both relatively safe; however, these population-based data suggest that stenting is the safer alternative with regard to mortality.
This study found no difference in stroke, MI, stroke/death, and stroke/death/MI comparing redo CEA vs CAS. The difference in mortality described above was attenuated in the composite outcomes. Stroke, MI, stroke/death, and stroke/death/MI rates were similar to the findings from other, albeit smaller, observational studies. [5] [6] [7] [8] 11, [20] [21] [22] [23] The range of stroke/death rates reported from the existing studies was 1.2% to 7.1% for redo CEA and 1.4% to 5.5% for CAS compared with 2.7% for CEA and 1.9% for CAS in the current study. The stroke rates for CEA and CAS from the current study also fall within the acceptable limits stated by intersocietal guidelines. 19 The foregoing implies equivalence of redo CEA and CAS with respect to stroke and their relative safety in this regard. Of the stroke events recorded after CEA, 95% occurred #30 days of surgery. Only 1 stroke (5%) occurred >30 postoperative days compared with 11 (31%) for CAS; hence, efforts to improve stroke outcomes after redo CEA should focus on the immediate postoperative period. Similar to patients with de novo carotid stenosis, our results show that 68% of redo CEA and 66% of redo CAS procedures were performed in asymptomatic patients. [24] [25] [26] [27] Symptoms had no effect on outcomes in this study. Despite the trend suggestive of higher stroke for asymptomatic (2.2%) compared with symptomatic (1.2%) patients who underwent CEA (P ¼ .26), symptomatic status was not a significant predictor of adverse outcomes after either procedure. This is contrary to the findings in the general and high-risk subpopulations of patients with de novo carotid lesions in which preoperative symptoms were a significant predictor of adverse outcomes. [24] [25] [26] [27] Nonetheless, that >66% of patients who received treatment for carotid restenosis were asymptomatic attracts some concern. This proportion was likely driven by high-grade stenosis, because >90% of asymptomatic patients had significant (>70%) restenosis. Our propensity score-matched comparison of select redo CEA and CAS patients revealed similar outcomes for CEA and CAS at 30 days and at 1 year. The difference in results between the population-based study and the propensity score-matched subcohort analyses suggests that there are patients in the general population who contribute excess mortality to CEA relative to CAS. One potential marker for such patients is ASA class. This study revealed ASA class IV patients (ie, patients with severe systemic disease that is a constant threat to life) were more prevalent in the CEA (21%) than in the CAS (11%) cohorts (P < .001). This class of preoperative physical status was associated with a twofold increase in postoperative mortality compared with patients in ASA class III. This questions the value of CEA in these sick patients, especially when they are asymptomatic. We recommend caution when offering redo CEA to very sick patients to improve overall outcomes for this treatment alternative.
Active smoking remains a key modifiable risk factor for adverse outcomes after redo CEA, as has been shown for de novo carotid disease. 28 This finding is also likely related to the predictive value of chronic obstructive pulmonary disease for patients who underwent CAS. The negative effect of smoking gives credence to the need for vascular surgeons and interventionists to contribute actively to multidisciplinary efforts to help patients quit smoking. The avoidance of ballooning after stent deployment 29, 30 and the use of b-blockers 31 have been shown to positively affect CAS outcomes in patients with de novo disease. These might also be useful in further improving outcomes after treatment of restenosis with CAS. This study has some limitations. In performing this study, we considered the effect of confounding by indication, which is an inherent limitation to observational studies such as this one. We believe this had minimal effect on our results because the treatment groups were very similar, as reported in Tables I and II . Furthermore, CAS has been popularized as an alternative to CEA for high-risk patients. Such indication will imply higher mortality in the CAS group, and our report to the contrary suggests that confounding by indication is unlikely.
The VQI data do not contain records of duration between the primary CEA and secondary procedure (redo CEA or CAS). Thus, we are unable to evaluate the effect of early or late restenosis caused by intimal hyperplasia or atherosclerosis on these outcomes. As a result of incomplete data, we are also unable to ascertain the causes of death and the transient or persistent nature of cranial nerve injury. These leave room for further study.
Despite these limitations, we have studied a large contemporary, population-based cohort of redo CEA and CAS patients with similar demographic, comorbidity, and follow-up profiles. Although CEA and CAS have equivalent rates of stroke, the higher mortality and cranial nerve injury associated with redo CEA undermines the value of this treatment alternative. The residual equipoise from this study places a high premium on the development of prediction models that identify patients for whom one treatment might outperform the other, as has been done in other domains of carotid revascularization. 32 
CONCLUSIONS
In this population-based study, we have shown higher mortality but similar rates of stroke and MI associated with redo CEA compared with CAS after prior ipsilateral CEA. We recommend avoidance of redo CEA in very sick patients. Smoking cessation remains a potent target for improvement of outcomes of carotid revascularization in these patients. ) . The speaker presented a large series of redo carotid endarterectomies (CEA) vs stenting (CAS) from patients enrolled in the Vascular Quality Initiative (VQI) database. There were 2863 carotid interventions; 1047 were CEAs and 1816 were CAS. Your data showed perioperative stroke rates of 2.2% for CEA and 1.3% for CAS in asymptomatic patients and 1.2% vs 1.6% for symptomatic patients, which is extremely impressive. This is, perhaps, the best outcome of redo CEA or CAS that has been reported to date. You also reported a very low cranial nerve injury rate of 2.5% for redo CEA cases. Several individual single-center studies have reported on the outcome of redo CEA and CAS for post-CEA restenosis, with a low percentage of perioperative stroke and death; however, this series is the largest so far.
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Our group analyzed 192 patients who underwent CAS or reoperation and found that CAS was as safe as redo CEA; however, redo CEA had a higher incidence of transient cranial nerve injury. Meanwhile, CAS had a higher incidence of >50% in-stent restenosis. This was published in JVS in 2010. Again, we looked into a similar issue, 5 years later, where we analyzed the data of 435 CAS procedures, which were mainly done for post-CEA restenosis. We found that CAS was not only a feasible but also a durable, therapeutic option for these patients. This was published in the Journal of Endovascular Therapy in 2015. I have the following four questions for you:
First, I am not certain I would use the conclusion that restenosis rates were the same since these VQI data may not have defined restenosis and your follow-up was only 1 year. Similarly, you cannot conclude that late stroke/death might be the same. I would suggest a word of caution. What are your thoughts?
Second, since you don't have the time between the primary CEA and restenosis, I am not certain you can conclude that redo CEA and CAS have similar outcomes, because you may be dealing with different lesions or pathology.
Third, were the provider specialties similar for both the redo operation and CAS? In our two reported series, both the redo CEA and CAS were done by the same provider. Would this have impacted your outcomes?
Fourth, since the cranial nerve injury reported in your series was only 2.5%, I am wondering if some of these cases were not identified or recorded. This number is rather low, even lower than what has been reported with primary CEA.
I want to thank the Association for the honor and privilege of discussing this interesting paper, and I believe it will make a significant contribution to the literature in regard to this subject.
Dr Mahmoud B. Malas. Thank you so much, Dr AbuRahma. You have made several valid points. We acknowledge your extensive work on this subject. You have authored the largest institutional and regional series, which we have referenced in the manuscript. As far as your first question, in these data, restenosis at 1 year was 4% for redo CEA vs 2% for CAS. The difference was not statically significant. We agree that the follow-up duration of 1 year limits the conclusions that can be made from this study. However, our comparisons are valid up to 1 year postoperation/intervention, and analyses of outcomes beyond 1 year leave room for future study.
The second question you asked was about the timing of intervention. We have described this limitation in the manuscript. We do not have the interval between the initial carotid endarterectomy and reintervention. However, in VQI, there is a built-in variable for restenotic lesions vs atherosclerotic lesions. We have included this variable in our model, which resulted in no change in the outcomes.
With regard to your third question on the specialty of the operators performing CEA vs CAS, as a registry maintained by the Society for Vascular Surgery (SVS), the operators on the cases logged into the VQI system are mostly vascular surgeons. This relative homogeneity in provider specialty likely has minimal impact on outcomes. On a related note, provider experience might be a useful consideration, and this leaves room for future study.
I agree with you on your last question on cranial nerve injury (CNI). The 2.5% rate of CNI following redo CEA could represent under-reporting. This likely represents that the majority of these injuries are minor and reversible. Another possible explanation is the extensive experience of the operators performing redo CEAs. While most of us avoid this operation, few believe it is safe in their hands. There are few reports in the literature, from single-surgeon experience, that show low CNI rate following redo CEA.
